MGC Pharmaceuticals Receives approvals for South Africa CimetrA trial
- MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial
- The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19
- Once completed, the trial will provide the data needed to plan future regulatory pathways to register CimetrA as a drug
- CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
- MGC Pharma is trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST
